July 2021

In the pre-pandemic old normal, for years the demand for the top performers in Clinical Development and Regulatory Affairs continued to out-strip supply. That demand had further intensified in the time of COVID, as pipelines expanded and the pursuit of new drug approvals intensified—regardless of Therapeutic Area focus. More recently there has also been a significant increase in demand for the elite leaders (in Biopharma as well as Med Devices) in the following functions as well:

You may also watch the full conversation detailing his leadership philosophy in our In The Spotlight interview here.